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CD8+ cytotoxic T lymphocyte (CTL) responses play an important role in controlling the replication of primate lentiviruses. Induction of these
responses is a key objective for most current AIDS vaccine approaches. Despite a variety of approaches for measuring properties and activities of
CTL, the functions responsible for controlling viral replication in vivo have not been clearly identified. Assays measuring CTL-mediated
suppression of viral replication in vitro are beginning to be used as possible correlates of in vivo virus suppressive activity, but the utility and
interpretive value of these assays are typically limited by properties of the cells that have been used. We investigated the capacity of SIV-specific
CTL clones (effectors), immortalized by transduction with human telomerase reverse transcriptase (hTERT), to suppress SIV replication in
autologous hTERT immortalized CD4+ T-cell clones (targets). Immortalized and non-immortalized SIV-specific effector cells showed IFN-γ
production and degranulation in response to viral antigen specific stimulation and significantly inhibited SIVmac239 replication (2 to 4 log
decrease in viral RNA or cell-associated proviral DNA) (pb0.0005). Our in vitro assays of inhibition of viral replication, using T-cell clones as
effectors and targets, provide a well-defined approach for evaluating possible mechanisms of CTL-mediated control of viral production which may
involve direct killing of infected target cells and/or release of proinflammatory cytokines such as IFN-γ and TNF-α. The use of hTERT
immortalized effector and target cells for such assays preserves relevant functional properties while providing a convenient, reproducible means of
conducting studies over time.
Published by Elsevier Inc.Keywords: AIDS; Human telomerase reverse transcriptase; Immortalized CD8+ T-cell clones; SIVIntroduction
Virus-specific CD8+ cytotoxic T lymphocytes (CTL) have
been ascribed a central role in the partial control of viral rep-
lication observed after infection with the human immunodefi-
ciency virus (HIV) (Day et al., 2007; Hoffenbach et al., 1989;
Kiepiela et al., 2007; Nixon et al., 1988; Walker et al., 1987,
1988; Wang et al., 2006; Zuniga et al., 2006) or the non-human
primate (NHP) equivalent, simian immunodeficiency virus (SIV)
(Jin et al., 1999; Lifson et al., 2001; Schmitz et al., 1999). Precise
characterization of the CTL response, both from the stand point
of antigen specificity and effector function, is therefore very im-⁎ Corresponding author. AIDS Vaccine Program, SAIC-Frederick, Inc., NCI-
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doi:10.1016/j.virol.2007.11.013portant for understanding the basis of control of viral replication
as well as in designing and evaluating potential vaccine can-
didates. Despite the availability of increasingly sophisticated
methods for characterizing various properties of CD8+ T cells
(Day et al., 2007; Lu and Andrieu, 2001; Nixon et al., 1988; Van
Baalen et al., 1998), the activities responsible for containment of
viral replication in vivo are not known with certainty, and the
properties measured in most in vitro assays are not directly re-
lated to in vivo relevant activities. An emerging approach to this
question is predicated on the notion that the best potential
correlate of the ability of CTL to limit viral replication in vivo is
likely to be the ability of CTL to limit viral replication in vitro. In
vitro models are therefore being developed for measuring CTL-
mediated control of viral replication using primary cell systems.
Studies using bulk peripheral blood mononuclear cells (PBMC)
(Chung et al., 2007; Tsubota et al., 1989; Van Baalen et al., 1998;
431J.T. Minang et al. / Virology 372 (2008) 430–441Walker et al., 1986), CTL lines or CTL clones (Ali et al., 2004;
Chung et al., 2007; Loffredo et al., 2006, 2005; Lu and Andrieu,
2001; van Baalen et al., 2002; Yang et al., 2003b) have shown the
potential to measure and analyze CTL activities in vitro. Data
from a number of in vitro studies using these methods have
suggested a positive association between viral antigen-induced
cytokine and/or proliferative responses by CTL in vitro and virus
control in vivo in humans (Day et al., 2007; Edwards et al., 2002;
Wang et al., 2006); the correlation is, however, not absolute. The
situation is even more controversial for SIV, with a positive
correlation between cytokine expression and control of viral
replication shown for some CTL clones and no correlation with
others (Chung et al., 2007; Loffredo et al., 2006). While these
disparities may be accounted for at least in part by differencesFig. 1. Frequency of SIV Gag p27 positive CD4+ T cells and levels of viral RNA and
transduced rhesus macaque CD4+ T-cell clone was infected with molecularly cloned
well tissue culture plates at 1×106 cells/well. The frequency of SIV Gag p27 express
cytometry (A). Viral RNA copies Eq/mL of culture supernatants (B) as well as prov
PCR and PCR as described (Lifson et al., 2003).between the assay systems employed (Chung et al., 2007; Day
et al., 2007), theymay also be a consequence of variable viability
and functional capacity of CTL lines or clones used as effectors
following extended propagation in vitro and the use of various
CD4+ cell types as targets.
Extensive or extended expansion of CTL clones for in vitro
proliferation, cytolysis or viral replication inhibition assays in
human or NHP studies is limited by the relatively short life
span of primary cell lines or CTL clones (Perillo et al., 1993,
1989), associated with a decrease in telomerase activity fol-
lowing multiple division cycles of T cells with resultant telo-
mere shortening (Weng et al., 1997), a prelude to senescence
and/or apoptosis. Overexpression of human telomerase reverse
transcriptase (hTERT) has been shown to prolong human Tproviral DNA expression peak around day 8 post infection in vitro. An hTERT
SIVmac239 (Kestler et al., 1990) using magnetic beads and then cultured in 24-
ing CD4+ T cells was determined 2, 5, 8 and 12 days post infection (PI) by flow
iral DNA copies/10,000 cells (C) were determined by real-time quantitative RT-
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2004, 2003; Hooijberg et al., 2000; Roth et al., 2003; Zhou
et al., 2005). Previous work from our group demonstrated that
transduction of antigen-specific human CD4+ T cells and CTL
for expression of hTERT effectively immortalized these cells,
allowing extended continuous in vitro propagation without
senescence, in marked contrast to non-transduced cells. Des-
pite immortalization, these cells were not transformed and
maintained the properties of the primary cells from which they
were derived, including maintenance of strict IL-2 dependence
and appropriate MHC-restricted antigen responsiveness (Bar-
sov et al., 2006).
These results were recently replicated and extended in rhesus
macaque CTL clones (Andersen et al., 2007). Similar growth
patterns, surface marker immunophenotype, cytolytic activities
and responses to antigen specific stimulation were demonstrated
for hTERT immortalized SIV-specific CTL clones and the
corresponding non-immortalized parental clones. While lysis of
cognate peptide-pulsed target cells or antigen-specific IFN-γ
production following stimulation with cognate peptide is rea-
sonable in vitro parameters to assess the potential of CTL to
control SIV replication in vivo (Chung et al., 2007; Day et al.,
2007), an in vitro assay system measuring the ability of im-
mortalized virus-specific CTL effectors to inhibit the replication
of SIV in infected autologous CD4+ T-cell targets can provide a
better platform to characterize the immunological mechanisms
of CTL-mediated viral control.
We therefore developed a robust and reproducible in vitro
viral replication inhibition assay using well-defined autologous
immortalized, clonal CD4+ T-cell targets and CTL effectors. We
report inhibition of SIV replication in infected CD4+ T-cell
targets by autologous hTERT-immortalized CTL clones at
levels comparable to that mediated by the corresponding non-
immortalized CTL clones. Immortalized CTL clones with a
preserved anti-viral function coupled with an in vitro survival
advantage (Andersen et al., 2007) would be a useful source of
consistent controls for in vitro assays of cellular immune
function and could facilitate molecular studies of anti-SIV CTL
activity.Fig. 2. SIVmac239-infected CD4
+ T-cell clones elicit CD107a and IFN-γ co-expres
transduced CD4+ T-cell clone was infected magnetically with molecularly cloned S
specific CTL clone (hTERT transduced) was added to the infected cells 8 days post
protein transport inhibitor (monensin). The frequency of CD107a and/or IFN-γ expre
T cells were used to estimate background levels of CD107a and/or IFN-γ.Results
An SIV infected CD4+ T-cell clone induces intracellular IFN-γ
and surface CD107a expression in an autologous SIV Gag
CM9-specific CTL clone
To determine the most appropriate time points for read
outs in our in vitro viral replication inhibition assay using clonal
T-cell populations, we assessed the kinetics of viral replication
in immortalized rhesus macaque CD4+ T-cell clones in vitro.
As shown in Fig. 1, SIV Gag p27 positive CD4+ T cells were
initially detected 5 days post infection (PI) and peaked between
days 7 and 9 PI (Fig. 1A). Similar to SIV Gag p27 staining, viral
RNA and proviral DNAwere detectable by day 6 PI and peaked
between days 8 and 12 PI (Figs. 1B and C). Background viral
RNA and cell-associated proviral DNA levels in the control
cultures of CD4+ T cells incubated with heat-inactivated virus
were highest in the first few days of the culture (days 1 to 4) and
then declined, reflecting decay of signal from residual inoc-
ulating virus, in contrast to the cultures with productive infec-
tion where the levels increased steadily and peaked on day 8 PI
(Figs. 1B and C). We therefore chose the time frame of days 7–
12 PI for our analyses in the in vitro viral inhibition assay as a
time when there was sufficient viral replication in positive con-
trol cultures to give readily measurable levels, and enough dy-
namic range to evaluate decreases with different experimental
conditions. Different CD4+ T-cell clones from the same monkey
or different clones from additional monkeys showed similar
susceptibility and kinetics of viral replication (data not shown).
We therefore used a single CD4+ T-cell clone for all subsequent
experiments.
Viral antigen-induced IFN-γ production by HIV/SIV-specific
CTL is frequently used as a baseline to estimate the in vivo
reactivity of virus-specific CTL (Chung et al., 2007; Day et al.,
2007). Therefore, prior to testing in an in vitro viral replication
inhibition assay, we evaluated an SIV Gag CM9-specific CTL
clone generated from a chronically infected rhesus macaque, for
reactivity to virally infected cells by assessing intracellular IFN-γ
and surface lysosomal associated membrane protein-1 (CD107a;sion in an SIV Gag181–189CM9-specific CD8
+ T-cell (CTL) clone. An hTERT
IVmac239, and cultured in 24-well plates. An autologous SIV Gag181–189CM9-
infection and the cells were cultured for an additional 5 h in the presence of a
ssing CTL was determined by flow cytometry. CTL exposed to uninfected CD4+
Fig. 3. An SIV Gag181–189CM9-specific CD8
+ T-cell clone suppresses SIV replication and spread in vitro in a dose-dependent manner. A CD4+ T-cell clone infected
magnetically with molecularly cloned SIVmac239 was added to uninfected CD4
+ T cells at a 1:25 ratio (i.e. 2×104 infected cells to 5×105 uninfected cells) in 24-well
tissue culture plates, and then co-cultured with an autologous SIV Gag181–189CM9-specific or allogeneic (allo) SIV Gag-specific CTL clone at different effector:target
ratios. Viral RNA copies/mL of culture supernatants (A) and proviral DNA copies/10,000 cells (B) were determined 7 days post infection by quantitative PCR.
Uninfected and infected CD4+ T cells cultured alone were included as negative and positive controls, respectively.
433J.T. Minang et al. / Virology 372 (2008) 430–441a CTL degranulation marker) expression following co-culture
with SIV infected autologous CD4+ T-cell clones. Both intra-
cellular IFN-γ and surface CD107a expression were induced in
the SIV Gag CM9-specific CTL by exposure to autologous SIV-Fig. 4. An hTERT immortalized and the non-immortalized parental SIV Gag181–189C
replication in vitro. An hTERT transduced CD4+ T-cell clone was incubated overni
(hTERT transduced and untransduced) or an allogeneic (allo) SIV Gag-specific CTL
RNA copies Eq/mL of culture supernatants (A) and proviral DNA copies/10,000 cells
infected CD4+ T cells cultured alone were included as negative and positive controls
experiments (C).infected CD4+ Tcells 7–9 days PI (correspondingwith peak viral
RNA and cell-associated proviral DNA levels; see Figs. 1B
and C). However, while most of the CTL responded to infected
target cells with the production of both IFN-γ and the CTLM9-specific CD8+ T-cell clone have comparable inhibitory effects on SIVmac239
ght with molecularly cloned SIVmac239, and then co-cultured with autologous
clones in 24-well tissue culture plates at two different effector:target ratios. Viral
(B) were determined 7 days post infection by quantitative PCR. Uninfected and
, respectively. Comparisons of mean viral RNA levels were for five independent
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duced only one or the other molecule. In general, a 10–13-fold
increase above background in the frequency of IFN-γ and/or
CD107a expressing CM9-specific cells was observed (Fig. 2).
A SIV Gag181–189CM9-specific CTL clone inhibits SIVmac239
replication in autologous CD4+ T-cell clones
To further characterize the antiviral potency of the SIV Gag
CM9-specific CTL clone (CM9-11), we assessed its capacity to
suppress SIVreplication in infected autologousCD4+ Tcells in an
in vitro viral replication inhibition assay. CTL-mediated viral
control was assessed by co-culturing autologous SIVmac239
infected CD4+ T cells mixed with uninfected CD4+ T cells at a
ratio of 1:25 with the CM9–11 CTL clone at different CD8+:
CD4+ T-cell ratios and measuring virus RNA copies or cell-
associated proviral DNA at day 12 PI. A dose-dependent in-
hibitory effect on viral replication was observed ranging from 100
to more than 10,000-fold reduction in viral RNA copies Eq/mLFig. 5. Addition of an SIV Gag181–189CM9-specific CD8
+ T-cell clone to a culture wi
transduced CD4+ T-cell clone was infected magnetically with molecularly cloned SI
autologous hTERT transduced SIV Gag181–189CM9-specific CTL clone added 1, 3 or
Gag p27 expressing CD4+ T cells was determined 12 days PI by flow cytometry (A
copies/10,000 cells (C) were determined by quantitative PCR. Uninfected and infe
controls, respectively.of culture supernatants for CD8+:CD4+ T-cell ratios of 0.01:1 and
1:1, respectively, compared to cultures of infected CD4+ T cells
alone or with allogeneic CTL (Fig. 3A). A similar reduction in
proviral DNA copies/10,000 cells was observed (Fig. 3B). The
antiviral effect of the CM9-11 clone was not discernible at CD8+:
CD4+ T-cell ratios of 0.001:1 or lower. Hence, in addition to
responding to infected autologous CD4+ T-cell clones with ele-
vated IFN-γ and surface CD107a expression, the CM9-11 CTL
clone effectively inhibits viral replication and spread in infected
target cells.
An hTERT immortalized SIV CM9-specific CTL clone retains
its full antiviral capacity
We recently developed an hTERT transduction procedure that
extends the life span of primate T-cell clones over untransduced
parental clones (Barsov et al., 2006). This approach preserves
antigen-specific IFN-γ responses of SIV-specific CTL clones
after more than 18 months in continuous culture, whereas theth established infection effectively suppresses SIVmac239 replication. An hTERT
Vmac239, and then cultured in 24-well tissue culture plates in the presence of an
6 days post infection (PI) at an effector:target ratio of 1:1. The frequency of SIV
). Viral RNA copies Eq/mL of culture supernatant (B) as well as proviral DNA
cted CD4+ T-cell clones cultured alone were included as negative and positive
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repeated stimulation (Andersen et al., 2007). To investigate if
hTERT immortalized CTL could inhibit SIV replication, we
compared the capacity for inhibition of SIV replication by an
immortalized CM9-specific CTL clone (CM9-11-TN) with the
untransduced parental clone (CM9-11) at different CD8+:CD4+
T-cell ratios. Quantitation of viral RNA expression and cell-
associated proviral DNA revealed greater than 3-log reduction in
viral RNA as well as proviral DNA using CM9-11-TN at CD8+:
CD4+ T-cell ratios of 1:1 and 0.2:1 compared to cultures with
infected CD4+ T cells alone or with allogeneic CTL (Figs. 4A
and B), and less reduction at lower ratios (data not shown). The
levels of viral RNA or cell-associated proviral DNA in cultures
of infected CD4+ T cells alone or with allogeneic CTL were
significantly higher than those in co-cultures with the autologous
SIV Gag CM9-specific CTL clone, CM9-11-TN ( pb0.0005;
Fig. 4C; and data not shown). No significant difference wasFig. 6. An SIV Gag181–189CM9-specific CTL clone shows higher viral replication
transduced CD4+ T-cell clone was infected magnetically with molecularly cloned SI
35SL8 (hTERT transduced and untransduced)-specific CTL clones in 24-well tissue
expressing CD4+ T cells was determined 8 days post infection by flow cytometry (A
copies/10,000 cells (C) were determined by quantitative PCR (B). Uninfected and in
viral RNA and proviral DNA expression.observed between cultures with infected CD4+ T cells alone
compared to cultures with allogeneic CTL. Noteworthy, these
levels of inhibition of viral replication were comparable with
those seen with the untransduced parental clone, CM9-11
(Figs. 4A and B). Hence, hTERT immortalization does not alter
the ability of primate T cells to suppress SIV infection in vitro
but provides a convenient, reproducible means of conducting
studies over time.
The SIV Gag CM9-specific CTL clone, CM9-11-TN, efficiently
clears virally infected CD4+ T cells when added to cultures
with an established infection
We have shown that effective inhibition of viral replication is
possible when an SIV Gag-specific CTL clone is added to
cultures of SIV-infected CD4+ T cells shortly after infection, a
time point at which very few cells are productively infectedinhibitory capacity than a Tat28–35SL8-specific CTL clone in vitro. An hTERT
Vmac239, and then co-cultured with autologous SIV Gag181–189CM9- or Tat28–
culture plates at an effector:target ratio of 1:1. The frequency of SIV Gag p27
). Viral RNA copies Eq/mL of culture supernatants (B) as well as proviral DNA
fected CD4+ T-cell clones cultured alone were used as controls of SIV Gag p27,
436 J.T. Minang et al. / Virology 372 (2008) 430–441(demonstrated by the paucity of SIV Gag p27 positive CD4+ T
cells; Fig. 1A). Thus, the CTL would only have to eliminate a
low number of infected cells in the culture to efficiently control
viral replication and spread. To determine if SIV Gag-specific
CTL can reduce virus output from a culture with an established
infection, a more rigorous task, we investigated the ability of the
CM9-11-TN clone to inhibit viral replication when added to
infected CD4+ T-cell cultures at a later time point, close to peak
infection (see Figs. 1A–C). Infected CD4+ T cells were co-
cultured with the autologous CM9-11-TN clone immediately
after infection or on day 3 or 6 PI at a CD8+:CD4+ T-cell ratio of
1:1. SIV Gag p27 staining at day 12 PI showed that fewer
infected cells were present in the cultures containing CTL than
in the control cultures without CTL (Fig. 5A). There was no
appreciable difference in the level of viral suppression, based on
the number of SIV Gag p27 positive CD4+ T cells, between the
cultures containing CTL added 1, 3 or 6 days PI, after taking
into account the lower number of surviving CD4+ T cells for the
later time points (Fig. 5A; percentage of CD4+ T cells in upper
left quadrant). This suggested that CM9-specific CTL can
effectively clear SIV infected cells both in early as well as near
peak infection. Similar to the infection data (frequency of SIV
Gag p27 positive cells), we observed close to a 4-log reduction
in proviral DNA copies/10,000 cells when CTL were added on
days 1 or 3 and a 2-log reduction for CTL addition on day 6 PI
(Fig. 5B). Together these data confirm the ability of CM9-11-
TN to eliminate virus-infected cells and, thereby, suppress virus
production and spread in CD4+ T cells when added to a culture
with a high frequency of infected target cells.
Tat SL8-specific CTL clones are potent inhibitors of SIVmac239
replication in vitro
Some studies have attributed more rapid and potent antiviral
effects of CTL specific for early SIVor HIV products (e.g. Tat)
compared with CTL reactive to late replication products (e.g.
Gag) (Ali et al., 2004; Loffredo et al., 2005). To assess this, we
compared the viral suppression properties of an hTERT
transduced (SL8-42-TN) and untransduced parental (SL8-42)
Tat SL8-specific CTL clone to those of the autologous CM9-11-
TN clone. An autologous SIV-infected CD4+ T-cell clone was
co-cultured within 1–2 h after infection with the parental SL8-
42, immortalized SL8-42-TN or CM9-11-TN clones at a CD8+:
CD4+ T-cell ratio of 1:1. The SL8-specific CTL clone strongly
inhibited virus replication with more than 98% reduction in the
frequency of SIV Gag p27 positive CD4+ T cells on day 8 PI,
comparable to the CM9-11-TN SIV Gag-specific clone
(Fig. 6A). The immortalized, SL8-42-TN, and the parental
SL8-42 clones inhibited viral replication to similar degrees with
2- to 3-log reductions in viral RNA or cell-associated proviral
DNA (Figs. 6B and C). However, we found a consistently
higher capacity for inhibition of SIV replication by the im-
mortalized Gag CM9-specific CTL clone compared to the Tat
SL8 clone, with a 4-log reduction in proviral DNA in the pre-
sence of CM9-11-TN compared with 2- to 3-log reduction for
SL8-42 (Fig. 6C; and data not shown). Thus, based on these two
clones, the CTL specific for an early SIV product (Tat) were lessefficient at suppression of SIV compared with a Gag- (SIV late
product) specific CTL.
Discussion
Here, we have developed a robust, reproducible in vitro
assay for measuring CTL-mediated viral suppression. In con-
trast to previous reports based on complex mixtures of peri-
pheral blood mononuclear cells as target cells (Chung et al.,
2007; Tsubota et al., 1989; Van Baalen et al., 1998; Walker
et al., 1986), we developed a simplified system using clonal
populations of infected CD4+ T-cell targets and virus-specific
CTL effectors. The system thus provides a consistent means of
evaluating the anti-viral activity of CTL using autologous
infected CD4+ target cells. This allowed measurement of what
is possibly the laboratory parameter most relevant to the ability
to suppress viral replication in vivo, i.e. the capacity of CTL to
limit viral replication in vitro. The use of clonal target and
effector populations also affords the opportunity to more easily
examine the molecular basis of CTL-mediated inhibition of
viral replication in infected cells.
Immortalization of the effector and target cell populations by
transduction with hTERT offers the potential for maintaining
defined, consistent cell populations for repeated, reproducible
testing over extended periods of time, as was also suggested
for HIV-specific CTL (Dagarag et al., 2003). Using our in vitro
viral replication inhibition assay,we assessed the ability of hTERT
immortalized rhesus macaque SIV-specific CTL to inhibit vi-
ral replication in autologous hTERT immortalized infected CD4+
T-cell clones. Viral replication inhibitory capacity was compar-
able for hTERT transduced and matching non-transduced CTL
clones specific for two immunodominant Mamu-A⁎01-restricted
SIVepitopes, Gag CM9 and Tat SL8. We used the immortalized
SIV Gag CM9-specific CTL clone, CM9-11-TN, to evaluate the
kinetics of CTL-mediated inhibition of virus replication in in-
fected target cells. Using this system, we found that the Gag-
specific CM9-11-TN CTL clone is able to suppress virus pro-
duction both when added at the initiation of infection, and several
days into the course of a spreading infection. Thus, even when
the virus is given a head start, this Gag-specific clone can sig-
nificantly suppress virus production. However, as expected,
delayed addition of the CTL clone to infected target cell cul-
tures allowed for greater spread of virus with more CD4+ target
cell loss, presumably reflecting death due to cytopathic effects
of the virus (Estaquier et al., 1994) or killing of an increased
frequency of infected CD4+ target cells by the CTL. The ef-
ficacy of CTL in reducing viral replication, even when added at
the peak of infection, suggests that the effector cells were not
anergized in the presence of high viral antigenic load in vitro as
suggested by data from in vivo studies (Fuller and Zajac, 2003;
Hegde and Robbins, 2001; Reignat et al., 2002). In a com-
plementary approach to studying the window of time during
which CTL are able to inhibit viral replication in virus infected
target cells, we removed CD8+ T cells by immunomagnetic
bead depletion after 1–2 days of co-culture with autologous
infected CD4+ T-cell targets and determined the frequency of
SIV Gag p27 positive CD4+ T cells on day 8 PI. Fewer infected
437J.T. Minang et al. / Virology 372 (2008) 430–441cells were seen on day 8 in the cultures with CTL, even when
the CTL were removed after the first 48 h of co-culture, com-
pared to target cells cultured alone (unpublished data). Thus,
addition of virus specific CTL early during infection, when
fewer target cells are productively infected (measured by Gag
p27 staining), can substantially inhibit viral replication and
spread with preservation of the uninfected CD4+ T-cell pool.
It has been proposed that CTL against HIV or SIV gene
products expressed early in the viral replication cycle, including
Tat, may have an advantage over CTL specific for late viral
gene products, such as Gag, due to the ability of CTL to mediate
killing of the infected cells prior to the production of progeny
virions that can infect other cells (Ali et al., 2004; van Baalen
et al., 2002, 1997; Yang et al., 2003b). We found that a CTL
clone specific for the regulatory gene product Tat was less ef-
fective at limiting virus spread than a Gag-specific clone in our
assay. In contrast, Loffredo et al. (2005), using polyclonal CTL
populations, reported greater antiviral capacity of Tat SL8-
specific compared to Gag CM9-specific C8+ T cells. Data from
a later study by the same group, also using CTL lines, showed
stronger viral replication inhibitory capacity of Gag CM9-
specific CTL over CTL specific to a number of early expressed
viral proteins such as Nef and Vif (Loffredo et al., 2006). We
observed, using clonal CTL populations as opposed to CTL
lines, a consistently higher viral replication inhibitory capacity
for a Gag CM9-specific CTL clone compared to a Tat SL8-
specific CTL clone. To exclude the possibility that the less ef-
ficient suppression by the SL8-specific CTL was due to the
emergence of escape mutations (Yang et al., 2003a), we per-
formed repetitive passages of virus obtained from CD4+ T cells
in the presence of saturating numbers of SL8-specific T cells.
We were not able to detect any escape mutations after 3 weeks
of culture, suggesting that mutations within the SL8 epitope
could not account for the difference in suppressive effect ob-
served between the SIV Gag CM9- and Tat SL8-specific CTL
clones in our short-term (8 day) assay (unpublished data). Our
data, while seemingly contradicting some early published re-
ports emphasizing target specificity as a primary determinant of
CTL efficacy, point to possible involvement of TCR avidity or
other clonotypic differences in the antiviral capacity of CTL.
Indeed, Chung et al., recently demonstrated significant dif-
ferences in anti-viral effects of different CTL clones specific to
the same SIV epitopes (Chung et al., 2007) suggesting that
variation in anti-viral efficacy may be influenced by properties
other than viral protein specificity. Another report suggested
that some HIV Gag-specific CTL could recognize infected cells
prior to virus integration and expression (Sacha et al., 2007),
thus indicating that recognition of virus infected cells might be
independent of viral replication. Thus, while it is important to
evaluate both the quality and magnitude of the in vitro re-
sponses of CTL clones specific to different SIVepitopes, it may
be too simplistic to attribute the differences in the magnitude of
the responses just to the epitope specificity (early versus late
viral replication product) without an analyses of a very large
number of clones. Examining several other independent Tat-
and Gag-specific CTL clones should shed more light on this
important subject and results from these experiments would bevery informative with regard to the design of vaccines and other
T cell based anti-viral therapies.
We show here induction of IFN-γ production in an SIV Gag
CM9-specific CTL clone by SIV-infected CD4+ T cells that
coincided with expression of the CTL degranulation marker,
lysosomal associated membrane protein-1 (CD107a). In line
with our observation of a higher viral replication inhibitory
capacity for the CM9-specific CTL clone compared to the SL8
specific clone, we found a greater frequency of the CM9-specific
CTL responding to the SIV infected CD4+ T cells with intra-
cellular IFN-γ and/or surface CD107a expression than the SL8-
specific CTL. Noteworthy, both CTL clones showed similar
IFN-γ responses to a saturating concentration (1 μg/mL) of
cognate peptide pulsed autologous-transformed B-cell lines,
mimicking the assay format typically used for assessment of
HIVand SIV specific CTL responses (data not shown). Besides
direct cytolytic effects of CTL on virus infected cells, CTL have
been suggested to indirectly inhibit viral replication in infected
cells or block viral spread via secreted molecules such as IFN-γ
(Chung et al., 2007; Day et al., 2007; Loffredo et al., 2006).
Indeed, it has been shown that although some CTL could
mediate the dual function of cytokine production and cytolysis,
these are two independent mechanisms of CTL function against
HIV infected cells (Buseyne et al., 1996; Yang et al., 1997).
However, IFN-γ responses by virus specific CTL have been
assessed mainly using cognate viral peptide-pulsed APC (An-
dersen et al., 2007; Gauduin et al., 1998; van Baalen et al., 1997).
Our data demonstrate that using virus infected target cells, as
opposed to APC pulsed with saturating concentrations of viral
peptide, to induce IFN-γ responses in virus-specific CTL pro-
vide a better estimate of the antiviral capacity of different CTL
clones. Whether the superior viral replication inhibitory capacity
as well as stronger IFN-γ and CD107a responses of the CM9-
specific clone is due to presentation of more MHC class I-CM9
peptide complexes on the infected cell surface or a higher
affinity to its epitope remains to be elucidated.
Our data reinforce the importance of functional in vitro assay
systems for assessing the antiviral capacity of virus-specific
CTL. The use of well defined clonal populations in our in vitro
viral replication inhibition assay makes it easier to evaluate
several factors that singly or in combination may have an impact
on the magnitude of T cell-mediated inhibition of viral repli-
cation. The improved survival capacity of the immortalized
CD4+ and CD8+ T cells during in vitro propagation makes them
very suitable for use in long-term analysis of antiviral T-cell
responses. The ability to conveniently immortalize CD4+ Tcells
for use as a consistent source of autologous targets in ex vivo
virus suppression assays, employing polyclonal CD8+ effector
cells obtained at different time points through the course of
vaccination or infection, may also help provide insights into the
nature of effector cells associated with antiviral activity. Cor-
relations of such data with control of viral replication in vivo
and other parallel ex vivo analyses of the same CD8+ T cell
samples using other assays may be of particular interest. Finally,
additional genetic manipulations (e.g. IL-2 insertion to ensure
constitutive expression) could be performed in concert with
hTERT immortalization to further enhance the viability of CTL
438 J.T. Minang et al. / Virology 372 (2008) 430–441clones for use in in vitro assays or for future in vivo adoptive
transfer experiments.
Materials and methods
Generation of SIV Gag181–189CM9 and Tat28–38SL8-specific
CD8+ and autologous CD4+ T-cell clones
SIV Gag181–189CM9- (CM9) and Tat28–35SL8- (SL8)
specific CTL clones were isolated from a Mamu-A⁎01 positive
Indian rhesus macaque, Macaca mulatta, chronically infected
with SIVmac239, as described previously (Andersen et al.,
2007). Briefly, isolated PBMC were stimulated for 1 week with
irradiated autologous PBMC pulsed with CM9 or SL8 peptide
(both from SynPep Corp., Dublin, CA). The cultures were
restimulated weekly with CM9 or SL8 peptide-pulsed and ir-
radiated autologous PBMC in the presence of recombinant
human IL-2 (50 IU/mL: NIH AIDS Research and Reference
Reagent Program). Following 2 rounds of restimulation, the
CM9- or SL8-specific CTL were cloned by limiting dilution
and maintained essentially as described in Riddell et al. (Riddell
and Greenberg, 1990) and Berger et al. (2001), using bi-weekly
anti-CD3 monoclonal antibody (mAb) (30 ng/mL) stimulation
with irradiated human PBMC and human Epstein Barr virus-
transformed B-cells (TM B-LCL; kindly provided by Drs. S.R.
Riddell and P.D. Greenberg, FHCRC, Seattle, WA) as feeder
cells, but without anti-CD28 mAb stimulation. APC and feeder
cells were irradiated in aMark I Cs137 gamma-irradiator (Shepherd
and Associates, San Fernando, CA) at 6000 rad (PBMCs) or
12500 rad (TM B-LCL). Positive wells were tested for antigen
specificity by flow cytometry using ICS for IFN-γ production
and CTL clonality was confirmed by staining with CM9 (Beck-
man Coulter, Miami, FL) or SL8 (NIH AIDS Research and
Reference Reagent Program) peptide/MHC-tetramers prior to
each experiment.
CD4+ T-cell clones were generated from Indian rhesus
macaque PBMC and splenocytes as described (Andersen et al.,
2007). Briefly, highly enriched CD4+ T cells were isolated from
PBMC and splenocytes by negative selection using Miltenyi
LD columns and anti-CD8 microbeads followed by positive
selection using MS columns and anti-CD4 microbeads (Mil-
tenyi Biotec Inc., Auburn, CA). CD4+ T-cell clones were ob-
tained after 2-week expansion in limiting dilution cultures
containing irradiated human PBMC, IL-2 and anti-CD3 mAb
and maintained as described above for CTL clones.
Immortalization of CD4+ and SIV-specific CD8+ T-cell clones
CM9- and SL8-specific CD8+ and autologous CD4+ T-cell
clones were transduced with a human telomerase reverse tran-
criptase/nerve growth factor receptor (hTERT/NGFR) construct
as described (Barsov et al., 2006). Transduction efficiency was
determined by surface staining for NGFR expression using anti-
human NGFR-PE (clone C40-1457; BD/PharMingen, San
Diego, CA). Transduced cells were further enriched by surface
staining with anti-human NGFR-PE followed by PE microbead
selection according to manufacturer's recommendation (Milte-nyi, Auburn, CA). The immortalized CTL and CD4+ T-cell
clones had been in culture for about 22 months prior to use in
the in vitro assays detailed below.
Virus stocks
The SIV isolate used in this study was derived from the
molecular clone SIVmac239 (Genbank accession no. M33262.1)
(Kestler et al., 1990). SIV virus stocks were produced by trans-
fection of HEK293T cells with the SIVmac239 molecular clone
using TransIt 293 reagent (Mirus Corporation, Madison, WI)
according to the manufacturer's recommendations. HEK293T
cells were maintained in high glucose or Dulbecco modified
Eagle medium (DMEM) supplemented with 10% heat-inacti-
vated fetal calf serum, 2 mM L-glutamine, 50 U of penicillin per
mL and 50 μg of streptomycin per mL (Invitrogen corp.,
Carlsbad, CA, USA). Virus was harvested on day 2 and titrated
on 24-well plates by serial end point dilutions using H9 cells as
previously described (Gorelick et al., 1990). Virus stocks were
stored in aliquots at −80 °C.
Infection of CD4+ T-cell clones with SIVmac239
CD4+ T-cell clones were activated with anti-CD3 mAb
(T-25 flask-bound: 5 μg/mL) and IL-2 (50 IU/mL) for 48 h
and then incubated with SIVmac239. Infections were carried
out either by incubating CD4+ T cells with aliquots of the virus
stock overnight (12–18 h) with 2 μg/mL polybrene or for 2–3 h
using the Viromag magnetofection reagents and procedures,
according to manufacturer's recommendation (OzBiosciences,
Marseille, France). Approximately 0.25 mL virus stock with
1.2×109 viral RNA copies Eq/mL was added per 1×106 CD4+
T cells (∼3×102 viral RNA copies/target cell). Virus exposed
CD4+ T cells were washed twice with sterile PBS to remove
any residual non-incorporated viral material, prior to use in
assays.
In vitro viral replication inhibition assay
SIVmac239-infected CD4
+ T cells were plated at 5×105 cells
per well in 24-well plates and co-cultured with autologous CTL
clones specific to SIV Gag (CM9) or Tat (SL8) epitope at a
CD8+:CD4+ T-cell ratio of 1:1 or as otherwise specified. SIV-
specific CTL clones derived from an unrelated Mamu-A⁎01
negative monkey were included in every experiment as allo-
geneic controls for non-MHC-restricted CTL effects. To test for
control of viral spread, 2×104 SIVmac239-infected CD4
+ Tcells
were added to 5×105 uninfected CD4+ T cells per well in 24-
well plates and co-cultured with autologous effector cells at
similar CD8+:CD4+ T-cell ratios stated above. Uninfected and
CD4+ T cells infected with SIVmac239 or exposed to heat-
inactivated SIVmac239 were cultured separately at 1×10
6 cells
per well as controls for viral infectivity. 1×106 CD4+ T cells
were incubated with 0.25 mL of heat-inactivated SIVmac239
with 2.8×108 viral RNA copies Eq/mL. The cultures were
maintained for 7 to 12 days with IL-2 addition every 2–3 days at
a final concentration of 50 IU/mL.
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staining and flow cytometry
Staining for surface markers (CD3 and CD4) and intracel-
lular SIV Gag p27 was performed to assess the levels of
SIVmac239 infection at different time points post infection (PI).
All antibodies were obtained from BD Biosciences (San Diego,
CA, USA) unless otherwise indicated. Cells were washed once
in FACS surface buffer (PBS, 1% rat sera, 1% mouse sera,
0.05% sodium azide) and a cocktail of mAbs to the following
surface markers conjugated to the indicated fluorochromes was
added: CD4-PE or PerCP-Cy5.5 (clone RPA-T4) and CD3-
APC (clone SP34-2). Cells were incubated for 30 min at 4 °C,
washed with sterile PBS and then fixed with 4% paraformalde-
hyde (PFA), 500 μL/sample tube for 30 min at 4 °C. The cells
were permeabilized (PBS, 0.1% saponin, 1% rat sera, 1%
mouse sera and 0.05% sodium azide), 1 mL/sample tube for
5 min, washed (0.1% saponin in PBS) and incubated with FITC
or PE conjugated anti-HIV Gag p24 mAb (Clone KC57,
Beckman Coulter, Fullerton, CA, USA); this mAb cross-reacts
with SIV Gag p27 (data not shown). A final wash was per-
formed and the cells were resuspended in 0.1% PFA. Samples
were acquired on a BD FACSCalibur flow cytometer (BD
Bioscience) and subsequent data analyses performed using FCS
Express Version 3 (De Novo Software, Thornhill, Ontario,
Canada). Dead cells were excluded from the analyses based on
forward versus side scatter gating, and at least 100,000 live cell
events collected for each sample.
Intracellular cytokine staining and degranulation assay
CTL were added (5×105 cells per well) to SIVmac239-
infected CD4+ T cells that had been in culture for 7 or 8 days
(when the frequency of SIV Gag p27 expressing target cells
was at peak levels for stimulation) at a CD8+:CD4+ T-cell ratio
of 1:1 in 24-well tissue culture plates. Uninfected autologous
CD4+ T cells were used as negative control antigen-presenting
cells for CTL stimulation. PE conjugated anti-human CD107a
mAb, 20 μL/test (clone H4A3), was added to the culture.
Monensin, 20 μL/test of a 1:20 dilution (Golgi stop™; BD
Bioscience), was added after an hour of incubation and the
cultures were incubated for an additional 4 h. Cells were
washed, and surface and intracellular stained, as described
above, with PerCP-Cy5.5 conjugated anti-human CD8 mAb
(clone RPA-T8) and FITC conjugated antihuman IFN-γ mAb
(clone 4S.B3), respectively. Samples were acquired and
analyzed as described above.
Viral load analysis
To monitor viral replication in vitro, culture supernatant was
collected at multiple time points between 2 and 12 days PI and
viral RNA was extracted from supernatant as described pre-
viously (Cline et al., 2005) with some modifications. Viral
replication was quantitatively measured by a FRET probe-based
real-time RT-PCR (TaqMan) assay described before (Cline
et al., 2005; Lifson et al., 2001). All PCR reactions were run onABI Prism 7700 Sequence Detection System and the fluor-
escent signal-based quantitation of viral RNA copy numbers in
test samples was determined by ABI sequence detection soft-
ware (Applied Biosystems, Foster City, CA).
Cell-associated DNA was extracted using the Qiagen DNA
Mini Kit as recommended by the manufacturer (Qiagen, Val-
encia, CA, USA). The copy numbers of SIV DNA (gag-specific
target) and that of the gene sequence for macaque CCR5, as
reference for cell equivalents, were co-determined in a duplex
format QPCR. The assay was as described by Cline et al. (2005)
with omission of the reverse transcription step, and with the
addition of primers (100 nM final concentration, each) and
probe (100 nM final concentration) specific for the macaque
CCR5 sequence and use of a cloned genomic fragment of the
rhesus macaque CCR5 gene as standard (Genbank Acc. No.
AF252567) (The Plasmid pR1-D, of the M. mulatta CCR5
gene, promoter region was a kind donation of Dr. Sunil K.
Ahuja of the University of Texas Health Science Center San
Antonio, San Antonio, TX) (Mummidi et al., 2000). The duplex
QPCR assay was run on an MX3000P™ instrument (Strata-
gene, La Jolla, CA) and results are reported as nominal SIV gag
DNA copy numbers per 10,000 cell equivalents determined
by copy numbers of the CCR5 sequence and based on 2 no-
minal copies of CCR5 per rhesus macaque cell (M. Piatak,
unpublished results).
Statistical analysis
Viral RNA and cell-associated proviral DNA levels were log
transformed prior to analyses. The threshold for viral replication
inhibition was arbitrarily set at a decrease of at least 2 logs (100-
fold) in viral RNA and/or cell-associated proviral DNA levels
for infected CD4+ T-cell clones co-cultured with virus-specific
CTL compared to infected CD4+ T-cell clones cultured alone.
Differences in measured parameters between cultures with
autologous CTL and cultures with allogeneic control CTL were
computed using the two-tailed Student's t-test. p values less
than 0.05 were considered significant. All tests were performed
using the software Statistica version 5.1 (StatSoft, Tulsa, OK,
USA).
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